AR112015A1 - Composiciones sólidas para administración oral - Google Patents

Composiciones sólidas para administración oral

Info

Publication number
AR112015A1
AR112015A1 ARP180101556A ARP180101556A AR112015A1 AR 112015 A1 AR112015 A1 AR 112015A1 AR P180101556 A ARP180101556 A AR P180101556A AR P180101556 A ARP180101556 A AR P180101556A AR 112015 A1 AR112015 A1 AR 112015A1
Authority
AR
Argentina
Prior art keywords
oral administration
solid compositions
glp
derivative
sglt2 inhibitor
Prior art date
Application number
ARP180101556A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59070439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR112015(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of AR112015A1 publication Critical patent/AR112015A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Composiciones sólidas para la administración oral que comprenden (i) un derivado de GLP-1 y el inhibidor de SGLT2 dapagliflozina, o (ii) un derivado de GLP-1 u una sal de NAC en combinación con un inhibidor de SGLT2.
ARP180101556A 2017-06-09 2018-06-08 Composiciones sólidas para administración oral AR112015A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175131 2017-06-09

Publications (1)

Publication Number Publication Date
AR112015A1 true AR112015A1 (es) 2019-09-11

Family

ID=59070439

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101556A AR112015A1 (es) 2017-06-09 2018-06-08 Composiciones sólidas para administración oral

Country Status (28)

Country Link
US (2) US11167014B2 (es)
EP (1) EP3634468B1 (es)
JP (1) JP7239495B2 (es)
KR (1) KR20200015564A (es)
CN (1) CN110769846A (es)
AR (1) AR112015A1 (es)
AU (1) AU2018280875A1 (es)
BR (1) BR112019025769A2 (es)
CA (1) CA3064677A1 (es)
CL (1) CL2019003402A1 (es)
CO (1) CO2019013047A2 (es)
DK (1) DK3634468T3 (es)
ES (1) ES2938050T3 (es)
FI (1) FI3634468T3 (es)
HR (1) HRP20230075T1 (es)
HU (1) HUE060962T2 (es)
IL (1) IL270812B2 (es)
MA (1) MA49253A (es)
MX (1) MX2019013965A (es)
MY (1) MY197488A (es)
PE (1) PE20200606A1 (es)
PH (1) PH12019550249A1 (es)
PL (1) PL3634468T3 (es)
PT (1) PT3634468T (es)
RS (1) RS64045B1 (es)
SI (1) SI3634468T1 (es)
TW (1) TWI797133B (es)
WO (1) WO2018224689A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11833248B2 (en) 2018-02-02 2023-12-05 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
WO2020130502A1 (ko) * 2018-12-21 2020-06-25 (주)휴온스 엠파글리플로진 및 시타글립틴을 포함하는 약학적 조성물
MX2022000827A (es) * 2019-08-07 2022-02-16 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.
JP2023502004A (ja) * 2019-11-07 2023-01-20 ノヴォ ノルディスク アー／エス Ｇｌｐ－１作動薬、ｓｇｌｔ２阻害剤、およびｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む固形組成物
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023123063A1 (en) * 2021-12-29 2023-07-06 Guangzhou Dazhou Biomedicine Ltd. Oral delivery
EP4299052A1 (en) * 2022-06-30 2024-01-03 Adocia Solid compositions comprising a peptide or a protein and a permeation enhancer
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
ATE309197T1 (de) 1999-02-05 2005-11-15 Emisphere Tech Inc Verfahren zur herstellung alkylierter salicylamide
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
US7262325B2 (en) 2000-06-02 2007-08-28 Emisphere Technologies, Inc. Method of preparing salicylamides
US6936590B2 (en) 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
KR20080102395A (ko) 2006-02-15 2008-11-25 베링거 인겔하임 인터내셔날 게엠베하 글루코피라노실-치환된 벤조니트릴 유도체, 당해 화합물을 함유하는 약제학적 조성물, 이들의 용도 및 이들의 제조방법
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
JP5021033B2 (ja) 2006-09-07 2012-09-05 エフ．ホフマン−ラ ロシュ アーゲー Ｓｎａｃ（サルカプロザートナトリウム）の製造法
AR065809A1 (es) 2007-03-22 2009-07-01 Bristol Myers Squibb Co Formulaciones farmaceuticas que contienen un inhibidor sglt2
WO2008144346A2 (en) 2007-05-18 2008-11-27 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for their preparation
ES2672770T3 (es) 2007-09-05 2018-06-18 Novo Nordisk A/S Derivados del péptido-1 similar al glucagón y su uso farmacéutico
US8685934B2 (en) 2009-05-27 2014-04-01 Bristol-Myers Squibb Company Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof
PT2498759T (pt) 2009-11-13 2018-11-15 Astrazeneca Uk Ltd Formulações de comprimidos de libertação imediata
JP6006118B2 (ja) 2009-12-16 2016-10-12 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アナログ及び誘導体
KR101925620B1 (ko) 2010-12-16 2018-12-05 노보 노르디스크 에이/에스 Ｇｌｐ-1 아고니스트 및 ｎ-(8-(2-히드록시벤조일)아미노)카프릴산의 염을 포함하는 고체 조성물
US20130035281A1 (en) * 2011-02-09 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9266940B2 (en) 2011-04-12 2016-02-23 Novo Nordisk A/S Double-acylated GLP-1 derivatives
WO2013032934A1 (en) 2011-08-26 2013-03-07 Aegis Therapeutics, Llc Compositions and methods thereof for oral administration of drugs
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
DK2827845T3 (en) 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
HRP20231613T1 (hr) 2012-03-22 2024-03-15 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
ES2871328T3 (es) 2012-06-20 2021-10-28 Novo Nordisk As Formulación de comprimido que comprende un péptido y un agente de suministro
CN105188736A (zh) 2013-03-20 2015-12-23 诺和诺德股份有限公司 胰岛素给药方案
CN106132985B (zh) 2014-04-07 2020-10-13 诺和诺德股份有限公司 双酰化glp-1化合物
CA2993215C (en) * 2015-07-02 2023-10-31 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN110099719A (zh) 2016-11-28 2019-08-06 诺和诺德股份有限公司 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素
WO2018096162A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec in cardiovascular conditions
WO2018096164A1 (en) 2016-11-28 2018-05-31 Novo Nordisk A/S Insulin degludec for treating diabetes
MX2022000827A (es) * 2019-08-07 2022-02-16 Novo Nordisk As Composiciones solidas que comprenden un agonista del peptido similar al glucagon (glp-1), un inhibidor del transportador de sodio-glucosa 2 (sglt2) y una sal del acido n-(8-(2-hidroxibenzoil )amino)caprilico.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11833248B2 (en) 2018-02-02 2023-12-05 Novo Nordisk A/S Solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid

Also Published As

Publication number Publication date
ES2938050T3 (es) 2023-04-04
MX2019013965A (es) 2020-01-23
TWI797133B (zh) 2023-04-01
PE20200606A1 (es) 2020-03-10
KR20200015564A (ko) 2020-02-12
HUE060962T2 (hu) 2023-04-28
US11167014B2 (en) 2021-11-09
TW201904583A (zh) 2019-02-01
IL270812A (en) 2020-01-30
MY197488A (en) 2023-06-19
RS64045B1 (sr) 2023-04-28
SI3634468T1 (sl) 2023-02-28
WO2018224689A3 (en) 2019-02-28
HRP20230075T1 (hr) 2023-03-17
JP7239495B2 (ja) 2023-03-14
CL2019003402A1 (es) 2020-03-20
CN110769846A (zh) 2020-02-07
DK3634468T3 (da) 2023-02-06
EP3634468A2 (en) 2020-04-15
IL270812B2 (en) 2024-01-01
EP3634468B1 (en) 2022-12-14
RU2019139082A (ru) 2021-06-02
BR112019025769A2 (pt) 2020-06-30
FI3634468T3 (fi) 2023-02-19
AU2018280875A1 (en) 2019-12-12
CO2019013047A2 (es) 2020-04-01
US20220016216A1 (en) 2022-01-20
RU2019139082A3 (es) 2021-09-16
CA3064677A1 (en) 2018-12-13
MA49253A (fr) 2020-04-15
PL3634468T3 (pl) 2023-03-13
PH12019550249A1 (en) 2020-07-13
PT3634468T (pt) 2023-03-28
JP2020522559A (ja) 2020-07-30
US20200147179A1 (en) 2020-05-14
IL270812B1 (en) 2023-09-01
WO2018224689A2 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
AR112015A1 (es) Composiciones sólidas para administración oral
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CO2019003182A2 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CR11418A (es) Trans-clomifeno para el sindrome metabolico
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
ECSP21026021A (es) Moduladores de la expresión de pnpla3
ECSP19072372A (es) Moduladores de la expresión de pcsk9
CO2021017317A2 (es) Células seguras e invisibles para el sistema inmunitario
GT200900153A (es) Agentes para combatir parasitos en animales
NI201900006A (es) Combinaciã“n de un inhibidor de bcl-2 y un inhibidor de mcl1, usos y composiciones farmacã‰uticas de ã‰stos
CL2021001246A1 (es) Moduladores de expresión irf5.
CL2018001157A1 (es) Formulación de combinación de dosis fija, eflornitina y sulindaco.
CO2020003134A2 (es) Moduladores de la expresión de enac
UY38472A (es) Moduladores de la expresión de foxp3
AR103484A1 (es) Triptólido y sus derivados en el tratamiento de tumores y patologías precancerosas de la piel
GB2543709A (en) Pharmaceutical agent
CL2019003288A1 (es) Una combinación farmacéutica para el tratamiento de un cáncer.
ZA201907789B (en) Solid compositions for oral administration
CL2019001859A1 (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta.
AR106415A1 (es) Composición farmacéutica para el tratamiento del dolor
BR112019002130A2 (pt) novo uso de n,n-bis-2-mercaptoetil isoftalamida
AR120063A1 (es) Células seguras e invisibles para el sistema inmunitario
CO2021004990A2 (es) Formulaciones de inhibidores de inmunoproteasomas

Legal Events

Date Code Title Description
FB Suspension of granting procedure